1 Use of tryptic peptide MALDI mass spectrometry imaging to identify the spatial 2 proteomic landscape of colorectal cancer liver metastases.

- 3
- 4 *Celine Man Ying Li^{1,2}, *Matthew T Briggs³, Yea-Rin Lee³, Teresa Tin², Clifford Young³, John Pierides⁴,
- 5 Gurjeet Kaur⁵, Paul Drew^{1,2}, Guy J Maddern^{1,2}, Peter Hoffmann³, Manuela Klingler-Hoffmann^{3#} and Kevin 6 Fenix^{1,2#}
- ^{1.} Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide, SA 5005, Australia.
- ^{2.} The Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, SA
 5011, Australia.
- ^{3.} Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia.
- ^{4.} SA Pathology, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia
- ^{5.} Institute for Research in Molecular Medicine, University Sains Malaysia, Pulau Pinang, 11800, Malaysia
- 13 (*) equal contribution.
- 14 #Correspondence: manuela.klingler-hoffmann@unisa.edu.au and kevin.fenix@adelaide.edu.au
- 15
- Keywords: Colorectal cancer liver metastasis, MALDI-MSI, LC-MS/MS, biomarkers, drug targets, colorectal
 cancer
- 18

19 Abstract

20

21 Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. CRC liver metastases 22 (CRLM) are often resistant to conventional treatments, with high rates of recurrence. Therefore, it is crucial to 23 identify biomarkers for CRLM patients that predict cancer progression. This study utilised matrix-assisted laser 24 desorption/ionisation mass spectrometry imaging (MALDI-MSI) in combination with liquid chromatography-25 tandem mass spectrometry (LC-MS/MS) to spatially map the CRLM tumour proteome. CRLM tissue 26 microarrays (TMAs) of 84 patients were analysed using tryptic peptide MALDI-MSI to spatially monitor 27 peptide abundances across CRLM tissues. Abundance of peptides was compared between tumour vs stroma, 28 male vs female and across three groups of patients based on overall survival (0-3 years, 4-6 years, and 7+ years). 29 Peptides were then characterised and matched using LC-MS/MS. A total of 471 potential peptides were 30 identified by MALDI-MSI. Our results show that two unidentified m/z values (1589.876 and 1092.727) had 31 significantly higher intensities in tumours compared to stroma. Ten m/z values were identified to have 32 correlation with biological sex. Survival analysis identified three peptides (Histone H4, Hemoglobin subunit 33 alpha, and Inosine-5'-monophosphate dehydrogenase 2) and two unidentified m/z values (1305.840 and 1661.060) that were significantly higher in patients with shorter survival (0-3 years relative to 4-6 years and 7+ 34 35 years). This is the first study using MALDI-MSI, combined with LC-MS/MS, on a large cohort of CRLM 36 patients to identify the spatial proteome in this malignancy. Further, we identify several protein candidates that 37 may be suitable for drug targeting or for future prognostic biomarker development. 38

- 38
- 39
- 40

41

42 Introduction

43

44 Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths 45 worldwide [1]. Approximately 50% of CRC cases metastasise to the liver [2]. CRC liver metastasis (CRLM) is 46 normally treated with surgical resection and chemotherapy. However, most CRLM cases present with multiple 47 liver metastases or have patients with poor health conditions that prevents surgery [3]. Most CRLMs ultimately 48 develop chemo-resistance [4]. Even with curative intent, CRLM has a relapse rate of 50% [5]. Together these 49 factors contribute to CRLM having a 5-year survival rate of 30% [2]. Currently, there are no predictive 50 biomarkers for CRLM recurrence or survival. CRLM surveillance currently involves frequent computed 51 tomographic (CT) scans and monitoring for blood carcinoembryonic antigen (CEA) levels [6, 7]. However, 52 these surveillance strategies have failed to detect early relapse, contributing to disease progression. Thus, there 53 is an urgent need for predictive markers for CRLM survival [5].

54

Quantitative image analysis for tissue histological biomarkers based on routine histochemistry or immunohistochemistry has been used for clinical diagnostics and biomarker research [8]. In cancer research, recent advances in mass spectrometry have made proteomics a useful approach for biomarker discovery [9, 10]. In particular, matrix-assisted laser desorption/ionisation (MALDI) mass spectrometry imaging (MSI) generates unbiased spatial intensity maps of molecules such as intact proteins, tryptic peptides, *N*-glycans, lipids or metabolites, which allows for the spatial mapping of tumour tissues. MALDI-MSI has been demonstrated to predict metastatic potential, disease recurrence, and survival in variety of primary cancers [11-13].

62

In the context of CRC, MALDI-MSI has been extensively applied to primary tumours and has identified 63 64 prognostic indicators for overall survival [14-16]. For example, multiple analytes have been shown to be 65 associated with clinical outcomes such as tumour stage, grade, metastasis, and cancer cell proliferation in primary CRC. However, there are a limited number of MALDI-MSI studies on CRLM. To the best of our 66 knowledge, only two reports have applied MALDI-MSI to detect lipid [17] and phospholipid [18] signatures on 67 68 CRLM tissue. These studies identified tumour localised lipid signatures that could have prognostic potential or 69 can be therapeutic targets. Whereas two additional MALDI-MSI studies identified the spatial proteome with 70 limited sample sizes preventing any correlation with survival [19, 20].

71

In this study, we applied tryptic peptide MALDI-MSI on a cohort of Australian CRLM patients and identified peptides that discriminate between tumour features, patient characteristics, and survival outcomes. Subsequently, liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed on tryptic peptides obtained from consecutive tissue sections to identify the associated proteins [21]. We identified discriminative proteins related to tumour features, and potential prognostic biomarkers that were associated with worse clinical outcomes in CRLM patients.

78

79 Material and Methods

81 Sample Collection and Tissue Specimens

82

83 A retrospective cohort of CRC patients with liver metastases were identified using the South Australian 84 Metastatic Colorectal Cancer Registry (SAmCRC) [22]. From that cohort, patients who had undergone liver 85 resection were selected for the study. Their corresponding FFPE tissue blocks were retrieved from SA 86 Pathology sites based at The Queen Elizabeth Hospital, Royal Adelaide Hospital and Flinders Medical Centre, 87 Adelaide, South Australia. Retrieved cases were reviewed by a clinical pathologist (J.P) for study suitability. 88 Demographics and clinicopathological characteristics of patients were shown in Table 1. This study was 89 approved by the Human Research Ethics Committee of the Central Adelaide Local Health Network under 90 protocol number 12237.

91

92 Tissue Microarray Construction

93

94 Previously selected tissue blocks were annotated by a pathologist (J.P), clearly distinguishing regions with 95 viable tumours from normal liver. Two tumour cores and one normal liver core per patient were inserted into the 96 TMA recipient block. Four TMA blocks were analysed, totalling 168 CRLM tumour cores from 84 patients. 97 TMAs were constructed using a TMA Master II (3DHISTECH, Budapest, Hungary). The completed block was 98 sealed with paraffin and stored at 4°C.

99

100 Hematoxylin and Eosin (H&E) Staining

101

102 FFPE tissue blocks were cut by microtome into 6 µm sections. They were first deparaffinized and rehydrated 103 with xylene for 3 x 5 mins, dipped in ethanol (100%) for 3 x 4 mins, ethanol (90%, v/v) for 2 mins, ethanol 104 (70%, v/v) for 2 mins, and washed with distilled water for 1 min. Subsequently, slides were stained with 105 hematoxylin for 5 mins, then washed with running tap water for 5 mins. Slides were then dipped into 0.3% 106 hydrochloric acid with ethanol (75%, v/v) for 10 seconds, followed by washing with tap water for 10 mins. 107 Tissues were stained with eosin for 1 min and washed with ethanol (100%) for 1 min. The H&E-stained TMA 108 slides were scanned by a NanoZoomer 1 Digital Slide Scanner (Hamamatsu Photonics K.K, Japan). Images 109 were acquired and viewed using NDP.view2 software (Hamamatsu).

110

111 Tryptic Peptide MALDI-MSI Sample Preparation

112

113 Tryptic peptide MALDI-MSI was performed on the sectioned TMAs following the protocol as previously 114 described, with minor modifications [23]. Briefly, $6 \mu m$ sectioned TMAs on indium tin oxide (ITO) slides were 115 washed with RCL premium grade xylene (100%) for 2 x 5 min, HPLC grade ethanol (100%) for 2 x 2 min, and 116 10 mM ammonium bicarbonate for 2 x 5 min. Slides were then boiled with 10 mM citric acid (pH 6) in a 117 conventional microwave (1250 W, Model MS2540SR, LG, China), followed by pulse-heating for 10 min and 118 heating at 98 °C on a heating block for 30 min. Slides were cooled down at room temperature prior to washing 119 with 10 mM ammonium bicarbonate for 2 x 1 min. Subsequently, slides were dried at ambient conditions,

120 marked with a water-based white-out, and scanned using a flattop scanner (Epson Perfection V600 Photo,

121 Model J25A, Epson, Indonesia) to teach the instrument during MALDI-MSI data acquisition.

122

Next, 20 μ g of trypsin gold (Promega) in 200 μ L of 25 mM ammonium bicarbonate and acetonitrile (10%, v/v) was deposited onto slides using an ImagePrep instrument (Bruker Daltonic, Germany) in 30 cycles with a fix nebulization time of 1.2 sec and drying time of 15 sec followed by incubation at 37 °C for 2 h in a humidified chamber containing potassium sulphate (53.3 g) and MilliQ water (18.2 g). Next, 7 mg/mL of alpha-cyano-4hydroxycinnamic acid (HCCA) in acetonitrile (50%, v/v) and trifluoroacetic acid (TFA, 0.2%, v/v) was deposited onto slides using an iMatrix Spray instrument (Tardo, Switzerland). Instrument-specific settings were as follows: 60 mm height, 1 mm line distance, 180 mm/s speed, 1 μ L/cm² density, 30 cycles and 15 sec delays.

- 131 MALDI-MSI Data Acquisition
- 132

133 MALDI-MSI data was acquired on a timsTOF fleX MS instrument (Bruker Daltonic, Germany), controlled by 134 timsControl (v3.0, Bruker Daltonics) and flexImaging (v7.0, Bruker Daltonics) in positive mode in the mass 135 range of m/z 700-3200. The instrument was calibrated using an internal calibrant [24]. Instrument-specific 136 settings were as follows: a transfer time of 180 µs, a pre-pulse storage of 25 µs, a collision RF of 4000 Vpp, a 137 collision energy of 10 eV, a funnel 1 (accumulation) RF of 500 Vpp, a funnel 2 (analysis) RF of 500 Vpp, a 138 multipole RF of 500 Vpp and a quadrupole ion energy of 5 eV. Laser power was set at 60% and pixel resolution 139 at 50µm.

140

141 MALDI-MSI Data Analysis

142

143 MALDI-MSI data was imported into SCiLS Lab v2023a (Bruker Daltonics, Germany) and pre-processed by 144 TopHat baseline subtraction and root mean square (RMS) normalisation. Individual TMA cores were annotated 145 based on pathological annotations by a pathologist (G.K.) from consecutive H&E-stained images scanned with 146 NanoZoomer (Hamamatsu). The feature finding tools were then used to create a list of putative peptides. The 147 feature finding uses the T-Rex² algorithm, and very strong filtering with 5% coverage and 0.5% relative 148 intensity threshold were applied. For comparisons of peak intensities between the groups, the RMS normalised 149 average spectra of each mass was exported as Excel files and statistical analysis performed using GraphPad 150 Prism (v 9.0, San Diego, CA).

151

152 LC-MS/MS Sample Preparation

153

154 CRLM TMAs were sectioned using a microtome (Microm HM 325) at $6 \,\mu$ m thickness and placed directly into

155 1.5 mL Eppendorf Protein LoBind Tubes. Paraffin was removed by the addition of 100 μ L of xylene (100%) for

156 2 min and 100 μ L of ethanol (100%) for 2 min. Sections were then rehydrated by the addition of 100 μ L of

157 Milli-Q water (100%) for 2 x 2 min and 100 μL of 50 mM ammonium bicarbonate (100%) for 2 x 2 min. Then

158 the tissue was boiled in 30 μL of 10 mM citric acid at pH 6 at 98 °C for 20 min in a Thermomixer (1500 rpm),

159 followed by 80 °C for 2 h. Tubes were cooled to room temperature and then centrifuged at 20,000 x g and 4 °C

160 for 30 min. Proteins were denatured from the tissue by adding 30 μ L of 8 M urea, followed by incubation at 161 room temperature for 30 min. Subsequently, samples were analysed using a modified tryptophan assay to 162 determine protein concentrations [25].

163

Protein reduction was by incubation with 2.5 μ L of 0.2 M dithiothreitol (DTT) at room temperature for 1 hr on a Thermomixer (500 rpm). Proteins were then alkylated by the addition of 2.8 μ L of 0.275 M 2-chloroacetamide (CA) and incubation in the dark for 30 min on a shaking Thermomixer. Protein digestion was performed with sequencing grade trypsin (Promega, USA) (1:50) at 37 °C overnight on a shaking Thermomixer, with digestion stopped by the addition of 10% formic acid (5 μ L). Finally, tryptic peptides were desalted using C18 ZipTips (Millipore, Ireland) according to the manufacturer's instructions.

170

171 LC-MS/MS Data Acquisition

172

173 LC-MS/MS analysis was conducted on an EASY-nLC 1200 system coupled to an Orbitrap Exploris 480 mass 174 spectrometer (Thermo Scientific, Bremen, Germany). Peptides (approximately 500 ng) were resuspended in 0.1% 175 formic acid and loaded onto a 25 cm fused silica column (75 µm inner diameter, 360 µm outer diameter) heated 176 to 50 °C. The column was packed with 1.9 µm ReproSil-Pur 120 C18-AQ particles (Dr. Maisch, Ammerbuch, 177 Germany). Peptides were separated over a 30 min linear gradient (3 to 24% acetonitrile in 0.1% formic acid) at a 178 flow rate of 300 nL/min. A compensation voltage of -45 V was applied from a FAIMS Pro interface (Thermo 179 Scientific) to minimise the impact of interfering ions before implementing a data-independent acquisition (DIA) 180 MS method. Briefly, an MS scan (m/z 395 to 905) was acquired at resolution 30000 (m/z 200) in positive ion 181 mode before isolated precursors (50 x 10 m/z windows, 1 m/z overlap) were fragmented with higher energy 182 collision dissociation (27.5% normalised collision energy). The resulting MS/MS spectra (m/z 145 to 1450) 183 were measured at resolution 22500.

184

185 LC-MS/MS Data Analysis

186

Raw data files were processed with Spectronaut v17.4.230317 (Biognosys AG, Schlieren, Switzerland). A direct DIA+ analysis was conducted by searching a UniProt human proteome database (Release 2022_04, 20607 canonical entries) with BGS factory settings. We manually matched single charged m/z values obtained from the MALDI-MSI data with singly charged m/z values calculated from doubly or triply charged peptides identified using Spectronaut analysis peptides with a peptide tolerance of +/- 16 ppm.

192

193 **Results**

194

195 Identification of tryptic peptide signatures in CRLM samples using MALDI-MSI.

196

To identify tryptic peptides associated with CRLM, we first constructed four TMAs from 84 CRLM patients consisting of 168 CRLM tumour tissue cores (two per patient, Table 1). The TMAs were sectioned onto conductive ITO slides and prepared for MALDI-MSI analysis. A comprehensive and detailed MALDI-MSI

200 workflow is presented in Fig. 1A. For the analysis of the processed MALDI-MSI data, tumour cores were 201 annotated as tumour (cancer cell rich) and intratumoral stroma (cancer cell poor/free) regions in SCiLS Lab by 202 matching pathologist annotated H&E regions overlaid with the MALDI-MSI optical image (Fig. 2). 203 Subsequently, the feature finding tool in SCiLS Lab was used to generate a list of 471 putative peptides by 204 applying very strong filtering with 5% coverage and 0.5% relative intensity threshold. Next, the receiver 205 operating curve (ROC) discriminating feature tool was used to identify m/z values with the highest area under 206 the curve (AUC) when comparing between tumour and stroma, male and female patients and across three 207 groups of patients' overall survival (0-3 years, 4-6 years, and 7+ years). Furthermore, denatured proteins from 208 consecutive tissue sections were then digested in-solution into tryptic peptides for LC-MS/MS analysis to 209 identify proteins by matching peptide sequences with measured m/z values by MALDI-MSI (Fig. 1B). To 210 achieve an extensive list of peptides identified by LC-MS/MS, the raw data was analysed in Spectronaut and 211 resulted in the identification of 3332 proteins from CRLM samples.

212

213

214

215 First, to identify tryptic peptides that significantly distinguished between tumour and stroma, we selected 216 MALDI-MSI m/z values with the highest AUC values to discriminate the two regions. From this analysis, 20 217 m/z values had AUC values of >0.5 which were then investigated further if they have significant abundances in 218 the CRLM tissues (Table 2). The 20 m/z values were observed between a m/z range of 1000 to 2300 (Fig. 3A-B). 219 Subsequently, a ROC plot with associated AUC values for each peptide was generated to plot the specificity and 220 sensitivity in relation to tumour and stroma. Of the 20 m/z values, m/z 1589.876 with 0.618 AUC (95% CI: 221 0.563-0.674), and m/z 1092.727 with 0.562 AUC (95% CI: 0.504-0.620) were found to be high in intensity in 222 tumour regions relative to stroma regions. Unfortunately, m/z 1589.876 and m/z 1092.727 could not be 223 identified from the LC-MS/MS data (Fig. 3C-F). The remaining 18 m/z values with AUC values >0.5 were not

Identification of tryptic peptides associated with CRLM tumour regions.

- statistically significant (Table 2 and Supp. Fig 1).
- 225

226 Identification of tryptic peptides associated with biological sex.

227

228 Next, we determined if there were differences in the spatial proteome between male and female CRLM tumour 229 tissues. Selecting, MALDI-MSI peaks with an AUC of >0.5 resulted in the identification of 14 m/z values. From 230 this analysis, 8 m/z values (m/z 2211.113, 1296.682, 1570.676, 1669.829, 1461.702, 1465.697, 1235.618, and 231 1366.628) were found to be significantly different in the tumour region between males and females with AUC 232 values between 0.600-0.695 (Table 3 and Supp. Fig. 2). Interestingly, we identified 4 (*m/z* 2211.113, 1296.682, 233 1570.676, 1366.628) to be higher in intensity in females (Fig 4A-D), whereas another 4 (m/z 1669.829, 234 1461.702, 1465.697, 1235.618) were higher in intensity in males (Fig. 4E-H). In the stroma (Supp. Fig. 3), 8 235 (m/z 2211.113, 1296.682, 1570.676, 1669.829, 1465.697, 1366.628, 1661.060 and 1305.840) were identified to 236 be statistically different between male and females, with 6 (m/z 2211.113, 1296.682, 1570.676, 1366.628,237 1661.060 and 1305.840) higher in females (Fig 5A-F) compared to 2 (m/z 1669.829 and 1465.697) in males (Fig 238 5G-H). The AUC values ranged from 0.633-0.677.

240 In total 10 unique m/z values were identified to discriminate between male and female tissues (Table 3). Six of 241 the 10 m/z values were associated with biological sex regardless of the region type (tumour or stroma). Using 242 LC-MS/MS, we identified 3 peptides, [FTTDAIALAMSR] (m/z 1296.682) from Proteasome subunit beta type-9 243 (PSMB9), [SDLVNEEATGQFR] (m/z 1465.697) from Carcinoembryonic antigen-related cell adhesion 244 molecule 5 (CEACAM5), and [YHLGAYTGDDVR] (m/z 1366.628) from Tryptase beta-2 (TPSB2) or Tryptase 245 alpha/beta-1 (TPSAB1), while the corresponding peptides for m/z 2211.113, m/z 1570.676 and m/z 1669.829 246 could not be identified. Further, an unidentified m/z value (m/z 1461.702) and [MVNHFIAEFK] (m/z 1235.618) 247 from Heat shock cognate 71 kDa protein (HSPA8) were higher in male tumour regions, while two unidentified 248 m/z values (1661.060 and 1305.840) were higher in female stroma regions. Together, these results indicated that 249 biological sex could contribute to changes to both the overall and region-specific tumour proteome.

250

251 Identification tryptic peptides linked to survival.

252

253 To identify potential prognostic markers for CRLM, we classified our patient cohort into 3 groups based on 254 survival (0-3 years, 4-6 years, and 7+ years). Specific to the tumour region (Supp. Fig 4), we identified 6 m/z255 values that had an AUC >0.5 between 0-3 and 7+ years survival. From this list, 5 m/z values (m/z 1325.754, 256 1529.738, 1481.857, 1305.840 and 1661.060) achieved statistical significance (Table 4). [DNIQGITKPAIR] 257 (m/z 1325.754) from histone H4 had the highest AUC value of 0.720 (95% CI: 0.6320-0.8086) (Fig. 6A). 258 Additionally, [VGAHAGEYGAEALER] (m/z 1529.738) from Haemoglobin subunit alpha (HBA1), 259 [REDLVVAPAGITLK] (*m*/*z* 1481.857) from Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2), and 2 260 unidentified m/z values (m/z 1305.840 and 1661.060) were all relatively high abundant in patients who had poor 261 survival outcomes (0-3 years post-surgery) compared to those who have survived for 7 or more years (Fig. 6). 262 Analysing the stromal regions (Supp. Fig. 5), only histone H4 replicated the tumour analysis showing higher 263 abundance in patients with poor (0-3 years) survival outcomes (Supp. Fig. 6). Together, our MALDI-MSI 264 analysis identified peptides that associated with duration of survival in CRLM patients.

265

266 **Discussion**

267

268 CRLM is a highly lethal and heterogeneous disease with poor prognostic tests available [26, 27]. While previous 269 studies have reported on the use of MALDI-MSI in CRLM tissue, most have used small sample sizes to only 270 describe the proteomic landscape of CRLM [19, 20]. To the best of our knowledge, this study is the first study 271 to utilise MALDI-MSI combined with LC-MS/MS to identify potential protein biomarkers in CRLM patients. 272 Furthermore, we applied this technology on the largest cohort of CRLM patients collected in Australia.

273

The tumour-stroma ratio is a well-known independent prognostic indicator for CRC, with high levels of stroma associating with poor survival [28, 29]. Thus, we determined if there are consensus proteins that could

discriminate between the two regions in our heterogenous CRLM sample cohort by MALDI-MSI. MALDI-MSI

analysis between tumour and intratumoral stroma regions, identified peptides that associate with tumour regions.

Among the 20 m/z values identified using MALDI-MSI, 2 (m/z 1589.876 and 1092.727) reached statistical

significance, however it was not possible to establish matches with our LC-MS/MS data. Nevertheless, our
 MALDI-MSI data was able to find features that distinguish tumours from stroma.

281

282 While it is widely appreciated that biological sex can greatly affect cancer biology and treatment outcomes [30, 283 31], proteomic analyses that describe such contributions, especially in CRLM, are rarely reported. In this study, 284 we investigated if biological sex was associated with differences in the spatial proteome of CRLM. We 285 identified PSMB9, CEACAM5 and TPSB2/TPSAB1 and 3 unidentified m/z values (m/z 2211.113, 1570.676 286 and 1669.829) that had significant differences in abundance between male and female CRLM tissues. These 287 were sex-specific for both tumour and stroma regions. Interestingly, HSPA8 and an unidentified m/z value (m/z) 288 1461.702) localised to tumours specific to males, and 2 unidentified m/z values (m/z 1305.840 and 1661.060) 289 localised to stroma, that were specific to females. Together these results show for the first time that biological 290 sex may have an underappreciated role in the spatial proteome of CRLM that may have currently unknown 291 consequences to its pathophysiology. Further research is required to determine if expression of these proteins 292 affect sex specific CRLM progression and treatment outcomes.

293

294 We report that histone H4, HBA1, IMPDH2, and two unidentified m/z values (m/z 1305.840 and 1661.060) are 295 more abundant in tumour tissues of CRLM patients with poor survival. In this study, only histone H4 expression 296 in tumour and/or stroma was enriched in patients that survived for >3 years. Histones are key epigenetic 297 regulators. Their post-translational modifications (acetylation, methylation and phosphorylation) can be linked 298 with gene expression changes that lead to cancer progression including CRC and hence are being investigated 299 for their therapeutic and prognostic potential [32]. Histone H4 upregulation has been linked to platinum-based 300 chemotherapy resistance in malignancies [33] and may explain its association with poor prognosis in our patient 301 cohort. Interestingly, histone H4 was identified to be elevated in CRC patient plasma by mass spectrometry 302 (detecting the [DNIQGITKPAI] peptide sequence) [34], and ELISA [35]. Thus, histone H4 could potentially be 303 developed as a blood biomarker to identify CRLM patients with worse prognostic outcomes. The relationship 304 between histone H4 tumour tissue expression, plasma levels, and survival outcomes is unknown and warrants 305 further investigation. HBA1 is the alpha subunit of hemoglobulin. Anaemia, measured by blood hemoglobulin 306 levels, has been linked with tumour hypoxia and poor outcomes in solid tumours [36]. However, the specific 307 contribution of HBA1 in cancer progression is unknown. Recent single cell RNA-sequencing analysis of gastric 308 cancers shows that HBA1 is overexpressed in gastric cancer cells. Importantly, patients with high tumour HBA1 309 expression led to poor overall survival supporting our findings in CRLM [37]. The contributions of IMPDH2 in 310 CRC progression is well established. IMPDH2 is an isoform of IMPDH, an enzyme critical for biosynthesis of 311 purine nucleotides and is essential for DNA synthesis [38]. IMPDH2 is commonly upregulated in malignancies 312 [39] including primary CRC [40]. IMPDH2 has been shown to promote CRC tumorigenesis [41], metastatic 313 potential [42] and in methotrexate resistance [43]. Thus, IMPDH2 has been previously implied as a potential 314 prognostic marker for CRC outcomes and may be useful as a drug target. Collectively, our study identified 315 previously reported and novel tryptic peptides candidates that may be able to predict poor outcomes in CRLM 316 patients. Considering the reported function of these proteins in cancer, these may also be used as novel targets in 317 CRLM therapy development.

319 In this study we used a manual indirect identification approach, where we matched the MALDI-MSI data with 320 data from an independent LC-MS/MS experiment. As part of this workflow, we have implemented internal 321 calibrants to allow high accuracy peptide matching [24]. However, there are limitations in this study to consider, 322 including the identification of peptides with the similar m/z values which fit within the same MALDI-MSI mass 323 tolerance window, therefore potentially resulting in mis-assignments. Additional validation by in situ tandem 324 MS fragmentation to confirm the identity of the peptides may improve peptide identification [44]. However, this 325 approach is only feasible for peptides with high signal intensity. Recently, several automated annotation tools 326 have been developed, which even include post-translational modifications [24, 45]. These tools might be used to 327 identify more of the 471 peptides from the LC-MS/MS data. Moreover, additional methods such as 328 immunohistochemistry could be employed to validate the abundance of the identified proteins in the metastatic 329 tumour regions. A second independent cohort of patients is required to validate our findings and confirm the 330 prognostic potential of the identified proteins that associated with poor CRLM survival outcomes. Nonetheless, 331 this study provides novel and valuable insights into CRLM biology and identifies potential prognostic 332 biomarkers and targets that are needed in CRLM.

333

334 Conclusions

335

In summary, this is the first study to utilise MALDI-MSI with LC-MS/MS to identify potential spatial proteomic tissue biomarkers in the largest cohort of Australian CRLM patients to date. Using these workflows, spatial proteomic features present in CRLM were revealed and changes within the tumour proteome identified in relation to clinical features, including sex and overall survival. Importantly, we reveal that biological sex could impact the spatial proteome profile of CRLM tumours and identified several proteins that associate with poor survival in CRLM patients. These findings should be further explored to identify new prognostic markers and therapeutic targets that are highly needed in CRLM.

344 **References**

- E. Morgan *et al.*, "Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN," *Gut*, vol. 72, no. 2, pp. 338-344, 2023, doi: 10.1136/gutjnl-2022-327736.
- H. Zhou *et al.*, "Colorectal liver metastasis: molecular mechanism and interventional therapy," *Signal Transduction and Targeted Therapy*, vol. 7, no. 1, p. 70, 2022/03/04 2022, doi: 10.1038/s41392-022-00922-2.
- 351 [3] Y. Dong and T. Gruenberger, "Surgical management of colorectal liver metastases a practical clinical approach," *European Surgery*, vol. 55, no. 3, pp. 94-99, 2023/06/01 2023, doi: 10.1007/s10353-023-00796-w.
- H. Zhou *et al.*, "Colorectal liver metastasis: molecular mechanism and interventional therapy," (in eng), *Signal Transduct Target Ther*, vol. 7, no. 1, p. 70, Mar 4 2022, doi: 10.1038/s41392-022-00922-2.
- T. Reinert *et al.*, "Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases," (in eng), *International journal of cancer*, vol. 150, no. 9, pp. 1537-1548, May 1 2022, doi: 10.1002/ijc.33924.
- J. H. Kang and S. H. Choi, "Imaging study for colorectal liver metastasis: beyond the diagnosis and to the prognosis," (in eng), *Hepatobiliary Surg Nutr*, vol. 8, no. 6, pp. 666-668, Dec 2019, doi: 10.21037/hbsn.2019.10.06.
- [7] K. Sasaki et al., "Pre-hepatectomy carcinoembryonic antigen (CEA) levels among patients 364 365 undergoing resection of colorectal liver metastases: do CEA levels still have prognostic implications?," (in eng), HPB : the official journal of the International Hepato Pancreato 366 Biliary 367 Association, vol. 18, no. 12, pp. 1000-1009, Dec 2016. doi: 368 10.1016/j.hpb.2016.09.004.
- H. Lee *et al.*, "Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder
 Urothelial Carcinoma Diagnosis by Liquid-based Cytology," (in eng), *Mol Cell Proteomics*, vol. 17, no. 9, pp. 1788-1802, Sep 2018, doi: 10.1074/mcp.RA118.000562.
- M. A. Reymond and W. Schlegel, "Proteomics in cancer," (in eng), *Adv Clin Chem*, vol. 44, pp. 103-42, 2007, doi: 10.1016/s0065-2423(07)44004-5.
- Y. W. Kwon *et al.*, "Application of Proteomics in Cancer: Recent Trends and Approaches for
 Biomarkers Discovery," (in English), *Frontiers in Medicine*, Review vol. 8, 2021-September 22 2021, doi: 10.3389/fmed.2021.747333.
- K. L. Sheng, L. Kang, K. J. Pridham, L. E. Dunkenberger, Z. Sheng, and R. T. Varghese, "An integrated approach to biomarker discovery reveals gene signatures highly predictive of cancer progression," *Scientific reports*, vol. 10, no. 1, p. 21246, 2020/12/04 2020, doi: 10.1038/s41598-020-78126-3.
- S. Meding *et al.*, "Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer," (in eng), *J Pathol*, vol. 228, no. 4, pp. 459-70, Dec 2012, doi: 10.1002/path.4021.
- A. C. Hristov *et al.*, "HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma," *Modern Pathology*, vol. 22, no.
 1, pp. 43-49, 2009/01/01 2009, doi: 10.1038/modpathol.2008.140.
- T. Gemoll, S. Strohkamp, K. Schillo, C. Thorns, and J. K. Habermann, "MALDI-imaging 388 [14] reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer," 389 390 41. 2015. Oncotarget, vol. 6, no. [Online]. Available: 391 https://www.oncotarget.com/article/6103/text/.
- A. Hinsch *et al.*, "MALDI imaging mass spectrometry reveals multiple clinically relevant masses in colorectal cancer using large-scale tissue microarrays," *Journal of Mass Spectrometry*, vol. 52, no. 3, pp. 165-173, 2017, doi: <u>https://doi.org/10.1002/jms.3916</u>.
- B. Martin *et al.*, "A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in
 UICC Stage I/II Colon Cancer," (in eng), *Cancers*, vol. 13, no. 21, Oct 26 2021, doi: 10.3390/cancers13215371.

- N. H. Patterson *et al.*, "Assessment of pathological response to therapy using lipid mass spectrometry imaging," *Scientific reports*, vol. 6, no. 1, p. 36814, 2016/11/14 2016, doi: 10.1038/srep36814.
- 401 [18] S. Shimma, Y. Sugiura, T. Hayasaka, Y. Hoshikawa, T. Noda, and M. Setou, "MALDI-based
 402 imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer
 403 liver metastasis," *Journal of Chromatography B*, vol. 855, no. 1, pp. 98-103, 2007/08/01/
 404 2007, doi: https://doi.org/10.1016/j.jchromb.2007.02.037.
- 405 [19] L. Moritz *et al.*, "Characterization of Spatial Heterogeneity in Metastasized Colorectal Cancer
 406 by MALDI Imaging," in *Preprints*, ed: Preprints, 2023.
- 407[20]A. Turtoi *et al.*, "Organized proteomic heterogeneity in colorectal cancer liver metastases and408implications for therapies," *Hepatology*, vol. 59, no. 3, pp. 924-934, 2014, doi:409https://doi.org/10.1002/hep.26608.
- R. Casadonte *et al.*, "Imaging mass spectrometry to discriminate breast from pancreatic cancer metastasis in formalin-fixed paraffin-embedded tissues," (in eng), *Proteomics*, vol. 14, no. 7-8, pp. 956-64, Apr 2014, doi: 10.1002/pmic.201300430.
- 413 [22] Y. Tomita et al., "Survival improvements associated with access to biological agents: Results 414 from the South Australian (SA) metastatic colorectal cancer (mCRC) registry," Acta 415 Oncologica, vol. 55, no. 4, pp. 480-485, 2016/04/02 2016, doi: 416 10.3109/0284186X.2015.1117135.
- T. W. Powers *et al.*, "MALDI imaging mass spectrometry profiling of N-glycans in formalinfixed paraffin embedded clinical tissue blocks and tissue microarrays," (in eng), *PLoS One*,
 vol. 9, no. 9, p. e106255, 2014, doi: 10.1371/journal.pone.0106255.
- 420 [24] J. O. R. Gustafsson *et al.*, "Internal calibrants allow high accuracy peptide matching between
 421 MALDI imaging MS and LC-MS/MS," (in eng), *J Proteomics*, vol. 75, no. 16, pp. 5093-5105,
 422 Aug 30 2012, doi: 10.1016/j.jprot.2012.04.054.
- J. R. Wiśniewski and F. Z. Gaugaz, "Fast and Sensitive Total Protein and Peptide Assays for
 Proteomic Analysis," *Analytical Chemistry*, vol. 87, no. 8, pp. 4110-4116, 2015/04/21 2015,
 doi: 10.1021/ac504689z.
- 426
 [26]
 J. Guinney *et al.*, "The consensus molecular subtypes of colorectal cancer," *Nature Medicine*,

 427
 vol. 21, no. 11, pp. 1350-1356, 2015/11/01 2015, doi: 10.1038/nm.3967.
- 428 [27] B. A. Alves Martins, G. F. de Bulhões, I. N. Cavalcanti, M. M. Martins, P. G. de Oliveira, and
 429 A. M. A. Martins, "Biomarkers in Colorectal Cancer: The Role of Translational Proteomics
 430 Research," (in eng), *Front Oncol*, vol. 9, p. 1284, 2019, doi: 10.3389/fonc.2019.01284.
- 431 [28] G. W. van Pelt *et al.*, "The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact," (in eng), *Histopathology*, vol. 73, no. 2, pp. 197-206, Aug 2018, doi: 10.1111/his.13489.
- K. Zhao *et al.*, "Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer," (in eng), *EBioMedicine*, vol. 61, p. 103054, Nov 2020, doi: 10.1016/j.ebiom.2020.103054.
- I. Baraibar *et al.*, "Sex and gender perspectives in colorectal cancer," (in eng), *ESMO Open*, vol. 8, no. 2, p. 101204, Apr 2023, doi: 10.1016/j.esmoop.2023.101204.
- 439 [31] C. H. Li *et al.*, "Sex differences in oncogenic mutational processes," *Nature Communications*, vol. 11, no. 1, p. 4330, 2020/08/28 2020, doi: 10.1038/s41467-020-17359-2.
- X. An, X. Lan, Z. Feng, X. Li, and Q. Su, "Histone modification: Biomarkers and potential therapies in colorectal cancer," *Annals of Human Genetics*, vol. 87, no. 6, pp. 274-284, 2023, doi: <u>https://doi.org/10.1111/ahg.12528</u>.
- R. Wang *et al.*, "Histone H4 expression is cooperatively maintained by IKKβ and Akt1 which attenuates cisplatin-induced apoptosis through the DNA-PK/RIP1/IAPs signaling cascade," *Scientific reports*, vol. 7, no. 1, p. 41715, 2017/01/31 2017, doi: 10.1038/srep41715.
- P. Van den Ackerveken *et al.*, "A novel proteomics approach to epigenetic profiling of circulating nucleosomes," *Scientific reports*, vol. 11, no. 1, p. 7256, 2021/03/31 2021, doi: 10.1038/s41598-021-86630-3.
- 450 [35] E. ÖZGÜR, M. KESKIN, E. E. YÖRÜKER, S. HOLDENRIEDER, and U. GEZER, "Plasma
 451 Histone H4 and H4K20 Trimethylation Levels Differ Between Colon Cancer and

452		Precancerous Polyps," In Vivo, vol. 33, no. 5, pp. 1653-1658, 2019, doi:
453		10.21873/invivo.11651.
454	[36]	S. Walrand, R. Lhommel, P. Goffette, M. Van den Eynde, S. Pauwels, and F. Jamar,
455		"Hemoglobin level significantly impacts the tumor cell survival fraction in humans after
456		internal radiotherapy," EJNMMI Research, vol. 2, no. 1, p. 20, 2012/05/19 2012, doi:
457		10.1186/2191-219X-2-20.
458	[37]	W. Yu, G. Chen, J. Yan, X. Wang, Y. Zhu, and L. Zhu, "Single-cell sequencing analysis
459		reveals gastric cancer microenvironment cells respond vastly different to oxidative stress,"
460		Journal of translational medicine, vol. 20, no. 1, p. 250, 2022/06/03 2022, doi:
461		10.1186/s12967-022-03411-w.
462	[38]	E. C. Thomas et al., "Different Characteristics and Nucleotide Binding Properties of Inosine
463		Monophosphate Dehydrogenase (IMPDH) Isoforms," PLOS ONE, vol. 7, no. 12, p. e51096,
464		2012, doi: 10.1371/journal.pone.0051096.
465	[39]	S. Kofuji and A. T. Sasaki, "GTP metabolic reprogramming by IMPDH2: unlocking cancer
466		cells' fuelling mechanism," The Journal of Biochemistry, vol. 168, no. 4, pp. 319-328, 2020,
467		doi: 10.1093/jb/mvaa085.
468	[40]	Y. He et al., "Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer
469		using immunoproteomics analysis," (in eng), Int J Colorectal Dis, vol. 24, no. 11, pp. 1271-9,
470		Nov 2009, doi: 10.1007/s00384-009-0759-2.
471	[41]	Q. Zhang et al., "c-Myc-IMPDH1/2 axis promotes tumourigenesis by regulating GTP
472		metabolic reprogramming," Clinical and Translational Medicine, vol. 13, no. 1, p. e1164,
473		2023. doi: https://doi.org/10.1002/ctm2.1164.
474	[42]	S. Duan <i>et al.</i> , "IMPDH2 promotes colorectal cancer progression through activation of the
475		PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways." Journal of Experimental &
476		Clinical Cancer Research, vol. 37, no. 1, p. 304, 2018/12/05 2018, doi: 10.1186/s13046-018-
477		0980-3.
478	[43]	S. Peñuelas, V. Noé, and C. J. Ciudad, "Modulation of IMPDH2, survivin, topoisomerase I
479		and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells." The
480		FEBS Journal, vol. 272, no. 3, pp. 696-710, 2005, doi: https://doi.org/10.1111/j.1742-
481		4658.2004.04504.x.
482	[44]	L. Théron <i>et al.</i> , "A Proof of Concept to Bridge the Gap between Mass Spectrometry Imaging.
483		Protein Identification and Relative Quantitation: MSI~LC-MS/MS-LF," (in eng), Proteomes,
484		vol. 4. no. 4. Oct 26 2016. doi: 10.3390/proteomes4040032.
485	[45]	G. Guo <i>et al.</i> , "Automated annotation and visualisation of high-resolution spatial proteomic
486	L - J	mass spectrometry imaging data using HIT-MAP," (in eng), Nat Commun, vol. 12, no. 1, p.
487		3241. May 28 2021. doi: 10.1038/s41467-021-23461-w.
488		- ,
180		
409		

490 **Statements and Declarations**

491

492 Funding

493 This work was supported by a Cancer Council SA Beat Cancer Infrastructure grant with matched funding 494 support from The Hospital Research Foundation Group (GM. and K.F.). K.F. was supported by a The Hospital 495 Research Foundation Group Early Career Fellowship. C.L. was supported by a University of Adelaide 496 Postgraduate Research Scholarship. The authors acknowledge Bioplatforms Australia, the University of South 497 Australia, and the State and Federal Governments, which co-fund the NCRIS-enabled Mass Spectrometry and 498 Proteomics facility at the University of South Australia.

499

500 Competing Interests

501 The authors have no relevant financial or non-financial interests to disclose.

503 Author Contributions

Conceptualisation C.L., M.B., M.K.H and K.F.; Collection and/or assembly of data: C.L., M.B., Y.L., T.T.,
C.Y., J.P., and G.K. Data Analysis and Interpretation: C.L., M.B., Y.L., C.Y., M.K.H, and K.F., resources: J.P.,
G.M., P.H, and K.F.; writing—original draft preparation, C.L., M.B., P.D., M.K.H and K.F.; writing—review
and editing, C.L., M.B., C.Y., P.D., M.K.H. and K.F.; supervision, P.H., G.M., M.K.H, and K.F., funding
acquisition, C.L., G.M., M.K.H and K.F.; All authors have read and agreed to the published version of the
manuscript.

511 Data Availability

The data underlying this article are available in this published article and its supplementary information files.
 Additional data are available upon request to the corresponding author.

Ethics Approval

This study was approved by the Human Research Ethics Committee of the Central Adelaide Local Health
Network under protocol number 12237.

519 Consent to Participate

Samples collected were retrospective patient tissues and was not consented as advised by our Human Research
 Ethics Committee.

- ---



549

550 Figures



Figure 1. Overview of (A) MALDI-MSI and (B) LC-MS/MS workflows for spatial mapping and
characterisation of tryptic peptides from CRLM FFPE tissues (n=84). Created with BioRender.com.

554



555

556 Figure 2. Representative scanned images of (A) H&E CRLM TMA cores, and (B) optical CLRM TMA cores.

557 CRLM tumour regions and CRC tumour regions (control) in (A) were annotated by a pathologist, as shown in

558 black and green, respectively. Scale bars (black lines) represent 3mm.



Figure 3. Identification of tryptic peptides associated with CRLM tumour regions using MALDI-MSI and LC-MS/MS. (A) Sum spectra of CRLM tumour (red) and (B) stroma (blue) in CRLM tumour cores. (C, D) H&E images (left) of a representative tumour core with tumour regions annotated in black and ion intensity maps (right) of most discriminative m/z values between tumour (red) and stroma (red). Tumour cores are 1.5mm in diameter. Bar graphs showing mean \pm SEM and ROC plots for (E) m/z 1589.876 and (F) m/z 1092.727. *p<0.05, ****p<0.0001. Student's t test. Each dot represents a single tumour core.

- 567
- 568
- 569
- 570



Figure 4. Significantly abundant tryptic peptides associated with male and female CRLM tumour regions, by MALDI-MSI and LC-MS/MS. (A) Representative H&E and ion intensity map of tumour region annotated CRLM tumour cores for m/z 2211.113. Tumour cores are 1.5mm in diameter. (A-D) Tryptic peptides (m/z2211.113, 1296.682, 1570.676, and 1366.628) significantly more abundant in females relative to males. Tryptic peptides were identified as (A) unidentified, (B) Proteasome subunit beta type-9, (C) unidentified, and (D) Tryptase beta-2 Tryptase alpha/beta-1. (E-H) Tryptic peptides (m/z 1669.829, 1461.702, 1466.697, and

586 1235.618) significantly more abundant in males relative to females. These tryptic peptides were identified as (E)

587 unidentified, (F) Carcinoembryonic antigen-related cell adhesion molecule 5, (G) Heat shock cognate 71 kDa

588 protein, and (H) unidentified. Bar graphs showing mean \pm SEM and ROC plots are presented. ****p<0.0001.

589 Student's t test. Each dot represents a single tumour core.





601 Figure 5. Significantly abundant tryptic peptides associated with male and female CRLM stroma regions, by

602 MALDI-MSI and LC-MS/MS. (A) Representative H&E and ion intensity map of stroma region annotated

603 CRLM tumour cores for m/z 1366.628. Tumour cores are 1.5mm in diameter. (A-F) Tryptic peptides (m/z

604 1366.628, 1296.682, 2211.113, 1570.676, 1661.060 and 1305.840) significantly more abundant in females

605 relative to males. Tryptic peptides were identified as (A) Tryptase beta-2 Tryptase alpha/beta-1, (B) Proteasome

subunit beta type-9, and (C-F) unidentified. (G-H) Tryptic peptides (m/z 1669.829 and 1461.702) significantly more abundant in males relative to females. These tryptic peptides were identified as (G) unidentified and (H)

608 Carcinoembryonic antigen-related cell adhesion molecule 5. Bar graphs showing mean \pm SEM and ROC plots

are presented. ****p < 0.0001. Student's t test. Each dot represents a single tumour core.





Figure 6. Significantly abundant tryptic peptides associated with poor overall survival (0-3 years) in CRLM tumour regions. CRLM cores were subdivided based on overall survival after curative-intent surgery (0-3, 4-6, and 7+ years). Representative H&E and ion intensity maps of tumour region annotated CRLM tumour cores for m/z 1325.754, 1529.738, 1481.857, 1305.840, and 1661.060. Tumour cores are 1.5mm in diameter. These tryptic peptides were identified as (A) Histone H4, (B) Haemoglobin subunit alpha, (C) Inosine-5'monophosphase dehydrogenase 2 and (D-E) unidentified by LC-MS/MS. Bar graphs showing mean ± SEM and ROC plots are presented. *p < 0.05, **p < 0.01. Ordinary one-way ANOVA. Each dot represents a single tumour core.

633 **Tables**

634

635 Table 1. Demographic and clinicopathological characteristics of Australian CRLM patient cohort (n=84).

Patients	n = 84
Age	
Median age	67
Age range	33-88
Early onset <50	6 (7.1%)
Late onset >50	68 (80.9%)
Missing	10 (11.9%)
Sex	
Female	25 (29%)
Male	59 (70%)
Overall survival (years)	
Median [Min, Max]	3.75 [0.36-11.94]
Mean (SD)	4.51 (2.9)
Survival groups	
0-3 years	25 (29.7%)
4-6 years	24 (28.6%)
7+ years	35 (41.7%)

No.	<i>m/z</i> Measured by MALDI- MSI	MALDI-MSI AUC (Tumour vs Stroma)	<i>p</i> -value	Enriched in Tumour vs Stroma	<i>m/z</i> Measured by LC-MS/MS	<i>m/z</i> Charge State (+2, +3)	Tryptic Peptide Sequence Confirmed by LC-MS/MS	Theoretical Singly Charged Tryptic Peptide <i>m/z</i>	<i>m/z</i> Error (ppm)	Protein Identified	Accession No.	Protein Coverage (%)		
1	1589.876	0.618	<0.0001*	Tumour				Unidentified						
2	1092.727	0.562	<0.050*	Tumour		Unidentified								
3	1305.840	0.558	0.053	-		Unidentified								
4	1529.738	0.545	0.135	-	510.583	10.583 +3 VGAHAGEYGAEALER			+2.6	Haemoglobin subunit alpha	P69905	71.1		
5	1661.060	0.553	0.079	-		Unidentified								
6	1368.638	0.544	0.147	-		Unidentified								
7	1198.710	0.536	0.233	-	599.856	+2	AVFPSIVGRPR	1198.706	+3.3	Actin, cytoplasmic 1 Actin, cytoplasmic 2	P60709 P63261	59.2 59.2		
8	1292.665	0.529	0.337	-	646.840	+2	DLQFVEVTDVK	1292.673	-6.2	Fibronectin	P02751	9.4		
9	1585.772	0.531	0.053	-		Unidentified								
10	1591.817	0.531	0.531	-	796.407	+2	EGYLQIGANTQAAQK	1591.807	+6.3	Liver carboxylestera se 1	P23141	27.0		
11	1641.805	0.525	0.414	-	821.402	+2	VDTNAPDLSLEGPEGK	1641.797	+4.9	Neuroblast differentiation -associated protein AHNAK	Q09666	31.7		
12	1706.776	0.527	0.371	-	853.899	+2	EGPVQFEEDPFGLDK	1706.791	-8.8	SNW domain- containing protein 1	Q13573	2.8		

636 Table 2. Tryptic peptides and proteins that discriminate between tumour and stroma regions in CRLM by MALDI-MSI and LC-MS/MS.

13	1280.719	0.521	0.485	-	640.864	+2	TEVIPPLIENR	1280.721	-1.6	Apolipoprotei n B-100	P04114	0.5
14	1481.857	0.528	0.355	-	494.628	+3	REDLVVAPAGITLK	1481.869	-8.1	Inosine-5'- monophospha te dehydrogenas e 2	P12268	4.5
15	1954.064	0.524	0.426	-	652.026	+3	VAPEEHPVLLTEAPLNPK	1954.064	0.0	Actin, cytoplasmic 1 Actin, cytoplasmic 2	P60709 P63261	59.2 59.2
16	2056.984	0.521	0.481	-	686.327	+3	LAEQAERYDEMVESMK K	2056.968	+7.8	14-3-3 protein epsilon	P62258	45.5
17	2211.113	0.532	0.287	-				Unidentified				
18	1325.754	0.513	0.680	-	663.380	+2	DNIQGITKPAIR	1325.754	0.0	Histone H4	P62805	54.4
19	1465.690	0.503	0.908	-	733.350	+2	SDLVNEEATGQFR	1465.692	-1.4	Carcinoembry onic antigen- related cell adhesion molecule 5	P06731	14.0
20	1833.902	0.500	0.996	-	611.979	+3	VFSNGADLSGVTEEAPL K	1833.923	-11.5	Alpha-1- antitrypsin	P01009	34.0

637 * Indicates statistically significant differences.

644 Table 3. Tryptic peptides and proteins that discriminate between biological sex in CRLM by MALDI-MSI and LC-MS/MS.

No.	m/z Measure d by MALDI- MSI	MALDI- MSI AUC Stroma (Male vs Female)	<i>p</i> -value	Stroma Enriched (Male vs Female)	MALDI- MSI AUC Tumour (Male vs Female)	<i>p</i> -value	Tumour Enriched (Males vs Female)	<i>m/z</i> Measure d by LC- MS/MS	<i>m/z</i> Char ge State (+2, +3)	Tryptic Peptide Sequence Confirmed by LC- MS/MS	Theoretic al Singly Charged Tryptic Peptide <i>m/z</i>	<i>m/z</i> Error (ppm)	Protein Identified	Accessio n No.	Protein Coverag e (%)
1	2211.113	0.633	0.0139*	Female	0.695	<0.0001*	Female				Uniden	tified			
2	1296.682	0.662	0.0053*	Female	0.687	<0.0001*	Female	648.834	+2	FTTDAIALAMSR	1296.662	+15.4	Proteasome subunit beta type-9	P28065	18.30
3	1570.676	0.645	0.0077*	Female	0.689	<0.0001*	Female				Uniden	tified			
4	1669.829	0.661	0.0029*	Male	0.683	<0.0001*	Male				Uniden	tified			
5	1461.702	0.563	0.2489	-	0.612	0.0064*	Male				Uniden	tified			
6	1465.697	0.638	0.0108*	Male	0.611	0.0072*	Male	733.350	+2	SDLVNEEATGQF R	1465.692	+3.4	Carcinoembry onic antigen- related cell adhesion molecule 5	P06731	14.0
7	1235.618	0.582	0.132	-	0.605	0.0111*	Male	618.316	+2	MVNHFIAEFK	1235.624	-4.9	Heat shock cognate 71 kDa protein	P11142	31.30
8	1366.628	0.677	0.0011*	Female	0.601	0.0145*	Female	683.823	+2	YHLGAYTGDDV R	1366.639	-8.0	Tryptase beta- 2 Tryptase alpha/beta-1	P20231 Q15661	24 24
9	1481.857	0.558	0.2874	-	0.551	0.2128	-	494.628	+3	REDLVVAPAGIT LK	1481.869	-8.1	Inosine-5'- monophosphat e dehydrogenase 2	P12268	4.5
10	1280.719	0.549	0.3971	-	0.550	0.2247	-	640.864	+2	TEVIPPLIENR	1280.721	-1.6	Apolipoprotein B-100	P04114	0.5
11	1441.676	0.557	0.2972	-	0.547	0.2542	-	721.343	+2	EFTPQMQAAYQ K	1441.678	-1.4	Hemoglobin subunit delta	P02042	40.10
12	1661.060	0.639	0.0105*	Female	0.520	0.6212	-				Uniden	tified			
13	1305.840	0.650	0.0056*	Female	0.505	0.8958	-			1	Uniden	tified	T		
14	1529.738	0.557	0.2972	-	0.502	0.9697	-	510.583	+3	VGAHAGEYGAE ALER	1529.734	+2.6	Hemoglobin subunit alpha	P69905	71.1

645 * Indicates statistically significant differences.

No	. m/z Measured by MALDI- MSI	MALDI- MSI AUC Tumour (0-3 vs 7+ Years)	<i>p</i> -value	MALDI- MSI AUC Tumour (0-3 vs 4-6 Years)	<i>p</i> -value	MALDI- MSI AUC Tumour (4-6 vs 7+ Years)	<i>p</i> -value	m/z Measured by LC- MS/MS	<i>m/z</i> Charge State (+2, +3)	Tryptic Peptide Sequence Confirmed by LC-MS/MS	Theoretical Tryptic Peptide <i>m/z</i>	<i>m/z</i> Error (ppm)	Protein Identified	Accession No.	Protein Coverage (%)	
1	1325.754	0.720	<0.0001*	0.547	0.3736	0.644	0.0132*	442.589	+3	DNIQGITKPAIR	1325.754	0.0	Histone H4	P62805	54.4	
2	1529.738	0.654	0.0031*	0.574	0.1602	0.594	0.1059	765.371	+2	VGAHAGEYGAEALER	1529.734	+2.6	Hemoglobin subunit alpha	P69905	71.1	
3	1481.857	0.624	0.0016*	0.573	0.1157	0.540	0.3445	494.628	+3	REDLVVAPAGITLK	1481.869	-8.1	Inosine-5'- monophosphate dehydrogenase 2	P12268	4.5	
4	1305.840	0.616	0.003*	0.558	0.211	0.551	0.2245	Unidentified								
5	1661.060	0.609	0.005*	0.555	0.2307	0.526	0.5366		Unidentified							
6	1589.876	0.594	0.0696	0.552	0.3281	0.665	0.0045*		Unidentified							

646 Table 4. Tryptic peptides and proteins that discriminate overall survival identified by MALDI-MSI and LC-MS/MS.

647 * Indicates statistically significant differences.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.24.24301748; this version posted January 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .